The prognosis of triple-negative breast cancer (TNBC) patients remains inferior to other clinical subtypes of breast cancers, in part because it lacks ER, PgR, and HER2, which can be targeted by endocrine therapy or anti-HER2 therapy [1]. This evidence concerns the gene ERBB2 and breast carcinoma.